Share this bulletin
Get news bulletins by email

Bulletin Nasdaq probed in Sweden for allegedly not reporting insider trading »

Investor Alert

New York Markets Open in:

Market Snapshot Analyst Ratings

Roche Holding AG ADR

OTC: RHHBY

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders

/marketstate/country/us

Roche Holding AG ADR

After Hours

RHHBY

/zigman2/quotes/208994986/delayed

35.48

Change

+0.03 +0.08%

Volume

Volume 2,337

Sep 20, 2023, 4:08 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/208994986/delayed

Previous close

$ 35.89

$ 35.45

Change

-0.44 -1.23%

Day low

Day high

$35.37

$35.87

Open: 35.78

52 week low

52 week high

$34.70

$43.32

Market cap

$231.60B

Average volume

1.57M

P/E ratio

19.19

Rev. per Employee

$624,885

EPS

1.85

Dividend

1.28

Div yield

2.28%

Ex dividend date

3/16/23

Compare:

Indexes

Dow(INDU) INDU
Nasdaq (COMP) COMP
S&P 500 (SPX) SPX
Global Dow (GDOW) GDOW

/news/latest/company/us/rhhby

MarketWatch News on RHHBY

Recursion Pharmaceuticals has a prescription for high drug costs: AI and 25 petabytes of data

12:38 p.m. Sept. 8, 2023

- Eleanor Laise
Gilead, Arcus, iTeos, other biopharmas get boost from accidental disclosure of Roche lung cancer trial data

8:45 a.m. Aug. 23, 2023

- Eleanor Laise
Regeneron Stock Slumps After FDA Decision Delays Blockbuster Release

4:51 p.m. June 27, 2023

- Barron's Online
Drugmakers Released a Ton of New Cancer Treatment Data. The Biggest Developments.

11:42 a.m. May 26, 2023

- Barron's Online
All Your Questions About Bird Flu, Answered

12:32 p.m. March 11, 2023

- Barron's Online
Our Roundtable Pros Scoured the Market. Here Are 26 of Their Top Stock Picks.

9:27 a.m. Jan. 23, 2023

- Barron's Online
Gilead Data Raise New Questions About Cancer Therapy

2:10 p.m. Dec. 20, 2022

- Barron's Online
It’s Jobs Day. Whatever the Market Says, Fed’s Still Bullish on Economy

7:52 a.m. Dec. 2, 2022

- Barron's Online
Alzheimer’s Breakthrough Is Boost for Biogen, Eli Lilly

10:26 a.m. Nov. 30, 2022

- Barron's Online
Biogen's New Alzheimer's Drug Faces Its Next Test. 5 Big Questions.

12:29 p.m. Nov. 28, 2022

- Barron's Online
Retailers Prepare for Another Reveal on Inflation. It’s Key Intelligence for the Fed.

9:33 a.m. Nov. 15, 2022

- Barron's Online
Biogen in Pole Position After Roche's Alzheimer's Drug Disappoints

11:47 a.m. Nov. 14, 2022

- Barron's Online
Elon Musk Looks Set to Put His Own Twist on Jobs Friday

6:39 a.m. Nov. 4, 2022

- Barron's Online
Tesla, Goldman Sachs, Netflix, AT&T, and Other Stocks to Watch This Week

8:46 a.m. Oct. 17, 2022

- Barron's Online
Stocks Poised to Open Higher

6:28 p.m. Oct. 16, 2022

- Barron's Online
3Q Earnings Season Begins with Reduced Expectations

9:30 p.m. Oct. 14, 2022

- Barron's Online
An Alzheimer’s Drug’s Big Surprise: How It Reset the Playing Field

6:33 p.m. Oct. 2, 2022

- Barron's Online
New Alzheimer's Drug Success Was a Shock. Now There Are 5 Big Questions.

2:20 p.m. Sept. 28, 2022

- Barron's Online
What’s Next for the Healthcare Industry, and How to Invest

9:47 a.m. Sept. 25, 2022

- Barron's Online
Can We Beat Alzheimer’s? Biogen and Eisai’s Latest Drug Trial Will Offer Clues.

9:30 p.m. Sept. 23, 2022

- Barron's Online
Loading more headlines...

Analyst Ratings

Foundation Medicine Set For 'Material Upside,' Cowen Says In Bullish Initiation

5:56 p.m. Feb. 15, 2018

- Benzinga.com
Analysts’ Updates after Sanofi’s Bioverativ Announcement

11:00 a.m. Feb. 7, 2018

- MarketRealist.com
Analyst Grows Cautious On Merck's Keytruda After Company Withdraws European Application

10:08 a.m. Oct. 30, 2017

- Benzinga.com

/news/nonmarketwatch/company/us/rhhby

Other News on RHHBY

Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion

4:15 p.m. July 14, 2023

- The Wall Street Journal Interactive Edition
New Gene Therapy Could Face Uphill Battle Despite FDA Approval

2:34 a.m. June 30, 2023

- The Wall Street Journal Interactive Edition
New Gene Therapy Could Face Uphill Battle

9:14 a.m. June 29, 2023

- The Wall Street Journal Interactive Edition
A Factory Exodus Is Hollowing Out Brazil’s Industrial Heartland

9:59 a.m. June 16, 2023

- The Wall Street Journal Interactive Edition
These Drugs Are So Futuristic That Doctors Need New Training

2:32 a.m. April 13, 2023

- The Wall Street Journal Interactive Edition
Bayer’s New American CEO to Study Wounded Pharma Giant Before Acting

10:36 a.m. June 5, 2023

- The Wall Street Journal Interactive Edition
Regeneron Borrows From Big Pharma Playbook

3:52 p.m. June 2, 2023

- The Wall Street Journal Interactive Edition
Amyloid Gains Converts in Debate Over Alzheimer’s Treatments

2:18 p.m. May 31, 2023

- The Wall Street Journal Interactive Edition
Bayer Hires Former Roche Executive to Succeed CEO Werner Baumann

2:35 p.m. Feb. 9, 2023

- The Wall Street Journal Interactive Edition
AbbVie Aims for New Drugs to Boost Sales

3:32 a.m. Feb. 7, 2023

- The Wall Street Journal Interactive Edition
What You Should Know About Treating Covid-19

5:20 p.m. Dec. 22, 2022

- The Wall Street Journal Interactive Edition
Moderna’s mRNA Cancer Vaccine Shows Promise in Preliminary Study

9:55 a.m. May 31, 2023

- The Wall Street Journal Interactive Edition
Exelixis (EXEL) Reports Data from CONTACT-01, QUARTZ-101 Study

3:01 p.m. Dec. 9, 2022

- Zacks.com
Anavex's (AVXL) Lead Alzheimer's Drug Meets Study Goal

2:03 p.m. Dec. 5, 2022

- Zacks.com
FDA Takes Tougher Line on Fast-Tracked Drugs

2:05 p.m. June 1, 2023

- The Wall Street Journal Interactive Edition
Oncolytics (ONCY) Up on Lead Drug Securing 2nd FDA Fast Track Tag

11:59 a.m. Dec. 2, 2022

- Zacks.com
Lilly's (LLY) Donanemab Betters Biogen's Alzheimer's Drug

9:09 a.m. Dec. 1, 2022

- Zacks.com
FDA Pulls Lilly’s Covid Antibody Drug

10:02 a.m. June 5, 2023

- The Wall Street Journal Interactive Edition
Newest Alzheimer’s Drugs Take Big but Fraught Step Toward Approval

9:35 p.m. May 31, 2023

- The Wall Street Journal Interactive Edition
Biogen's (BIIB) Lecanemab Shows Benefit but With Side Effects

9:53 a.m. Nov. 30, 2022

- Zacks.com
Loading more headlines...

/news/pressrelease/company/us/rhhby

Press Releases on RHHBY

Roche showcases commitment to advancing innovative diagnostic solutions at WorldLab-EuroMedLab

1:00 a.m. May 17, 2023

- PR Newswire - PRF
Genentech’s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions in People With Relapsing Forms of Multiple Sclerosis

1:00 a.m. May 17, 2023

- BusinessWire - BZX
FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)

1:00 a.m. May 9, 2023

- BusinessWire - BZX
New Vabysmo Data Suggest Greater Retinal Drying Versus Aflibercept in Wet Age-Related Macular Degeneration and Diabetic Macular Edema

3:00 p.m. April 25, 2023

- BusinessWire - BZX
Genentech Announces Industry-Leading Brain Health Research Collaborations and Latest Data Across Neuroscience Medicines at AAN 2023 Annual Meeting

8:00 a.m. April 24, 2023

- BusinessWire - BZX
FDA Approves Genentech’s Polivy in Combination With R-CHP for People With Certain Types of Previously Untreated Diffuse Large B-cell Lymphoma

3:40 p.m. April 19, 2023

- BusinessWire - BZX
Genentech’s Tecentriq Plus Avastin Reduced the Risk of Cancer Returning in People With Certain Types of Adjuvant Liver Cancer in a Phase III Study

11:00 a.m. April 16, 2023

- BusinessWire - BZX
Genentech Data Highlights Strength of Ophthalmology Portfolio and Commitment to Advancing Eye Care at ARVO 2023

1:00 a.m. April 13, 2023

- BusinessWire - BZX
New Four-Year Data for Genentech’s Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA)

2:00 a.m. March 20, 2023

- BusinessWire - BZX
Biotech Sector Working Fast to Combat Alzheimer's Disease Cases That are Set to Explode

9:00 a.m. March 15, 2023

- PR Newswire - PRF
FDA Advisory Committee Votes in Favor of the Clinical Benefit of Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma

7:45 p.m. March 9, 2023

- BusinessWire - BZX
Roche receives FDA approval of label expansion for VENTANA PD-L1 (SP263) Assay to identify patients with locally advanced and metastatic non-small cell lung cancer eligible for Libtayo

2:00 a.m. March 6, 2023

- PR Newswire - PRF
Roche joins forces with the U.S. Centers for Disease Control and Prevention to strengthen laboratory systems in the fight against the HIV and tuberculosis epidemics

2:00 a.m. Feb. 28, 2023

- PR Newswire - PRF
New Phase III Data Show Genentech’s Vabysmo Rapidly Improved Vision and Reduced Retinal Fluid in People With Retinal Vein Occlusion (RVO)

2:00 a.m. Feb. 10, 2023

- BusinessWire - BZX
Roche expands collaboration with Janssen to advance personalised healthcare through companion diagnostics

2:00 a.m. Feb. 9, 2023

- PR Newswire - PRF
Genentech Announces Positive Data From Global Phase III Program for Crovalimab in PNH, a Rare, Life-Threatening Blood Condition

2:15 a.m. Feb. 7, 2023

- BusinessWire - BZX
Genentech’s Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial

2:00 a.m. Jan. 19, 2023

- BusinessWire - BZX

Rates »

Mortgage Equity Savings Auto

National averages from Bankrate.com

MarketWatch.com

Follow MarketWatch
RSS
Podcasts

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

Roche Holding AG ADR

MarketWatch News on RHHBY

Analyst Ratings

Other News on RHHBY

Press Releases on RHHBY

Rates »

Latest News

dow

nasdaq

s&p 500

Kiosk